Characterization of the Biomechanical Properties of Skin Using Vibrational Optical Coherence Tomography: Do Changes in the Biomechanical Properties of Skin Stroma Reflect Structural Changes in the Extracellular Matrix of Cancerous Lesions?
actinic keratosis
basal cell carcinoma
collagen
epithelial cells
epithelial–mesenchyme transition
extracellular matrix
fibrous tissue
squamous cell carcinoma
stroma
vascular mimicry
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
17 11 2021
17 11 2021
Historique:
received:
28
10
2021
accepted:
12
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
13
1
2022
Statut:
epublish
Résumé
Early detection of skin cancer is of critical importance since the five-year survival rate for early detected skin malignancies is 99% but drops to 27% for cancer that has spread to distant lymph nodes and other organs. Over 2.5 million benign skin biopsies (55% of the total) are performed each year in the US at an alarming cost of USD ~2.5 B. Therefore there is an unmet need for novel non-invasive diagnostic approaches to better differentiate between cancerous and non-cancerous lesions, especially in cases when there is a legitimate doubt that a biopsy may be required. The purpose of this study is to determine whether the differences in the extracellular matrices among normal skin, actinic keratosis (AK), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) can be assessed non-invasively using vibrational optical coherence tomography (VOCT). VOCT is a new diagnostic technology that uses infrared light and audible sound applied transversely to tissue to measure the resonant frequencies and elastic moduli of cells, dermal collagen, blood vessels and fibrous tissue in skin and lesion stroma without physically touching the skin. Our results indicate that the cellular, vascular and fibrotic resonant frequency peaks are altered in AK, BCC and SCC compared to those peaks observed in normal skin and can serve as physical biomarkers defining the differences between benign and cancerous skin lesions. The resonant frequency is increased from a value of 50 Hz in normal skin to a value of about 80 Hz in pre- and cancerous lesions. A new vascular peak is seen at 130 Hz in cancerous lesions that may reflect the formation of new tumor blood vessels. The peak at 260 Hz is similar to that seen in the skin of a subject with Scleroderma and skin wounds that have healed. The peak at 260 Hz appears to be associated with the deposition of large amounts of stiff fibrous collagen in the stroma surrounding cancerous lesions. Based on the results of this pilot study, VOCT can be used to non-invasively identify physical biomarkers that can help differentiate between benign and cancerous skin lesions. The appearance of new stiff cellular, fragile new vessels, and stiff fibrous material based on resonant frequency peaks and changes in the extracellular matrix can be used as a fingerprint of pre- and cancerous skin lesions.
Identifiants
pubmed: 34827711
pii: biom11111712
doi: 10.3390/biom11111712
pmc: PMC8615800
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cells. 2019 May 01;8(5):
pubmed: 31052445
World J Radiol. 2016 Jan 28;8(1):59-72
pubmed: 26834944
Exp Cell Res. 2018 Jul 15;368(2):137-146
pubmed: 29674112
Skin Res Technol. 2019 Sep;25(5):743-749
pubmed: 31127665
J Am Acad Dermatol. 2020 Jan;82(1):110-116
pubmed: 31408683
Biomed Opt Express. 2014 Jun 09;5(7):2113-24
pubmed: 25071952
Int J Mol Sci. 2019 Jul 09;20(13):
pubmed: 31324051
BMC Cancer. 2016 Nov 4;16(1):841
pubmed: 27809802
An Bras Dermatol. 2019 Nov - Dec;94(6):637-657
pubmed: 31789244
JAMA. 2016 Jul 26;316(4):436-47
pubmed: 27458949
Br J Radiol. 2015 Oct;88(1054):20150344
pubmed: 26268142
Dermatology. 2017;233(1):64-73
pubmed: 28486238
Oncotarget. 2015 Aug 28;6(25):20946-58
pubmed: 26189182
Dermatol Surg. 2017 Nov;43(11):1348-1357
pubmed: 28562437
J Am Acad Dermatol. 2021 Sep;85(3):780-782
pubmed: 32860914
J Am Acad Dermatol. 2018 Jan;78(1):47-53
pubmed: 28947293
Integr Biol (Camb). 2015 Oct;7(10):1120-34
pubmed: 25959051
Nat Clin Pract Oncol. 2007 Aug;4(8):462-9
pubmed: 17657251
An Bras Dermatol. 2015 May-Jun;90(3):351-6
pubmed: 26131865
Nat Methods. 2014 Feb;11(2):183-9
pubmed: 24317254
Biochim Biophys Acta Biomembr. 2020 Sep 1;1862(9):183316
pubmed: 32360073
Skin Res Technol. 2021 Mar;27(2):227-233
pubmed: 32696597
Dermatol Pract Concept. 2014 Jul 31;4(3):11-24
pubmed: 25126452
Cell Rep. 2015 Dec 22;13(11):2456-2469
pubmed: 26670048
J Cell Biol. 2000 Feb 21;148(4):779-90
pubmed: 10684258
Curr Treat Options Oncol. 2018 Sep 20;19(11):56
pubmed: 30238167
Skin Res Technol. 2003 Feb;9(1):3-23
pubmed: 12535279
Br J Radiol. 2012 Nov;85(1019):1435-45
pubmed: 23091287
Dermatol Clin. 2017 Oct;35(4):417-437
pubmed: 28886798
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Biomed Mater Res A. 2017 Jun;105(6):1666-1671
pubmed: 28218484
Adv Skin Wound Care. 2020 Jun;33(6):307-312
pubmed: 32209812
Arch Dermatol. 2010 Mar;146(3):279-82
pubmed: 20231498
J Biomed Opt. 2013 Dec;18(12):121513
pubmed: 24343434
JAMA Intern Med. 2016 Oct 1;176(10):1435-1436
pubmed: 27459394
J Biophotonics. 2015 Apr;8(4):279-302
pubmed: 25412100
Bionanoscience. 2016;6:65-80
pubmed: 27014560
Oncogene. 2014 Jul 3;33(27):3496-505
pubmed: 23912450
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
Int J Cancer. 2020 Apr 15;146(8):2296-2304
pubmed: 31901133
Dermatol Pract Concept. 2020 Jun 29;10(3):e2020066
pubmed: 32642314
Dermatol Surg. 2007 Oct;33(10):1158-74
pubmed: 17903149
NeuroRx. 2005 Apr;2(2):215-25
pubmed: 15897946
PLoS One. 2009 Nov 30;4(11):e8027
pubmed: 19956566
Phys Med Biol. 2007 Mar 21;52(6):1565-76
pubmed: 17327649